Eckert & Ziegler Initiates Actinium-225 Production to Tackle Global Shortage

Berlin-based Eckert & Ziegler Radiopharma GmbH has announced the start of Actinium-225 (Ac-225) production, addressing a worldwide scarcity of this crucial radionuclide. This development emerges from a collaborative project with the Nuclear Physics Institute of the Czech Academy of Sciences. The company has also begun the process to achieve Good Manufacturing Practice (GMP) certification, aiming for market availability in the first half of 2025. This move could significantly benefit pharmaceutical firms focusing on alpha-emitting radiopharmaceuticals.

The innovative cyclotron-based production method is a notable advancement, converting Radium-226 into Ac-225. Dr. Lutz Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH, emphasized the importance of this milestone in enhancing cancer treatment through reliable isotope supply. The project underscores Eckert & Ziegler’s leadership in radioligand therapy development and solidifies its role as a major industry player.